Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

985.08
+7.830.80%
Post-market: 984.01-1.0700-0.11%19:59 EDT
Volume:1.98M
Turnover:1.96B
Market Cap:931.28B
PE:42.92
High:1,003.22
Open:980.13
Low:978.00
Close:977.25
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.92
T/O Rate:0.21%
Dividend:6.00
Dividend Rate:0.61%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:35.10
PE(LYR):42.92

Loading ...

Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain

TIPRANKS
·
Jan 22

Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential

TIPRANKS
·
Jan 22

Eli Lilly and Company to Announce Fourth-Quarter Financial Results

Reuters
·
Jan 21

Eli Lilly's (LLY.US) FRα ADC Receives FDA Breakthrough Therapy Designation

Stock News
·
Jan 21

Eli Lilly & Co (LLY) Gets a Buy from Bernstein

TIPRANKS
·
Jan 21

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Jan 21

Eli Lilly Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 20

Market Chatter: Abivax CEO Plays Down Eli Lilly Takeover Talk

MT Newswires Live
·
Jan 20

Eli Lilly’s sofetabart mipitecan receives FDA’s Breakthrough Therapy designation

TIPRANKS
·
Jan 20

FDA Grants Breakthrough Therapy Designation to Lilly's Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer

Reuters
·
Jan 20

Lilly's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Jan 20

Guggenheim Adjusts Price Target on Eli Lilly and Co. to $1,161 From $1,163, Maintains Buy Rating

MT Newswires Live
·
Jan 20

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Spyre Therapeutics (SYRE) and Astellas Pharma (OtherALPMF)

TIPRANKS
·
Jan 20

Eli Lilly’s New Dulaglutide Study Targets Real-World Safety Questions for GLP-1 Investors

TIPRANKS
·
Jan 17

Eli Lilly Stock (LLY) Falls 5% After FDA Delays Decision on Weight-Loss Pill

TIPRANKS
·
Jan 16

Eli Lilly & Co. Stock Falls 3.8%, Underperforms Peers

Dow Jones
·
Jan 16

Half of GLP-1 users ditch their injections - and some are turning to other weight-loss methods instead

Dow Jones
·
Jan 16

Lilly, Novo Sued Over GLP‑1 Drug Dominance By Compounding Pharmacy

Reuters
·
Jan 15